ClinicalTrials.gg
RecruitingNCT06131840Updated Jul 22, 2026

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

A Phase 1 interventional study of PF-08046050 and bevacizumab in Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung and Stomach Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Recruiting at 48 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
914
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Colorectal Neoplasms by Pfizer — 6 open to participants now, 14 under way, 3 of them phase 3. Colorectal Neoplasms · Pfizer.

Planned enrollment
Largest of 68
914 · median 72
Started
2023
with 2 others
Phase 1
32 of 73
2 open now
Primary completion
2029-09
later than 10 of 13 live
Registered
60th of 73
by date

Among the 73 studies in Colorectal Neoplasms by Pfizer, this one has the largest planned enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2023, is one of 32 in phase 1, reaches primary completion later than 10 of the 13 other live ones, and was the 60th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 73 studies in Colorectal Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Colorectal Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat.

Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs.

This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells.

This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body.

This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.

03

Conditions studied

  • Colorectal Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Stomach Neoplasms
  • Pancreatic Ductal Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Small Cell Lung Carcinoma

Keywords

  • CRC
  • NSCLC
  • PDAC
  • GC
  • GEJ
  • SCLC
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Tumor type:

    • Participants in Part A (dose escalation) and Part B (dose optimization) must have - or cytologically-confirmed or unresectable solid tumor . Must have , refractory, or progressive disease, and should have no appropriate standard therapy available.

      • Participants in Part A must have one of the following tumor types: colorectal cancer (CRC); gastric carcinoma (GC) or gastroesophageal junction adenocarcinoma (GEJ); non-small cell lung cancer (NSCLC); or pancreatic ductal adenocarcinoma (PDAC).
      • The tumor types to be enrolled in Part B will be identified by the sponsor from among those specified in Part A.
    • Participants in Part C (dose expansion) must have one of the following histologically- or cytologically-confirmed metastatic or unresectable solid tumor malignancies.

      • CRC (adenocarcinoma of the colon or rectum) and must have received no more than 2 prior chemotherapy regimens for the treatment of advanced colorectal cancer and evidence of either progressive disease or intolerance to their last regimen.
      • PDAC with one or more metastatic lesions measurable by computed tomography/magnetic resonance imaging according to v1.1 criteria; and must have received no more than 1 prior chemotherapy regimen for the treatment of advanced PDAC and evidence of either progressive disease or intolerance to that regimen.
      • GC or GEJ and must have received prior platinum and fluoropyrimidine-based chemotherapy.
      • NSCLC and must have received platinum-based therapy. If eligible and consistent with local standard of care must have received a /PD-L1 inhibitor. In addition, participants with tumor genomic mutations/alterations for which approved targeted therapies are available per local standard of care, must have received such therapies.
      • Small cell lung cancer (SCLC) and must have received platinum-based therapy for extensive-stage disease and no more than 3 . If eligible and consistent with local standard of care must have received a PD 1/PD-L1 inhibitor.
    • CRC participants in Part D and Part E (bevacizumab combination therapy) must have histologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. Received a maximum of 2 prior chemotherapy regimens for the treatment of advanced colorectal cancer and had demonstrated progressive disease or intolerance to their last regimen.
    • CRC participants in Part D and Part E (5FU/LV + bevacizumab and 5FU/LV + oxaliplatin + bevacizumab combination therapy) must have histologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. Must not have received a prior TOPO1 inhibitor (such as irinotecan or nanoliposomal irinotecan) in any setting. 1L cohorts: No prior chemotherapy for advanced disease. 2L cohorts (applicable to 5FU/LV + bevacizumab combination only): 1 prior chemotherapy regimen for the treatment of advanced disease, which must have included a fluoropyrimidine and oxaliplatin.

    > 2L PDAC participants in Part E (5FU/LV combination therapy) must have histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma. One or more metastatic lesions measurable by computed tomography/magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.

    > 1L PDAC participants in Part E (5FU/LV + oxaliplatin combination therapy) must have histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma that has not been previously treated in the metastatic setting. One or more metastatic lesions measurable by computed tomography/magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. No prior chemotherapy for PDAC with the following exception: Patients who received /neoadjuvant chemotherapy and who had recurrence more than 12 months after completion of adjuvant/neoadjuvant chemotherapy are eligible.

  2. Participants enrolled in the following study parts should have a tumor site that is accessible for (ies) and agree to biopsy(ies) and/or submission of archival tissue:

    • Monotherapy dose optimization (Part B)
    • Monotherapy (Part C) and combination therapy (Part E) disease-specific expansion cohorts
  3. An (ECOG) Performance Status score of 0 or 1
  4. per Response Evaluation in Solid Tumors (RECIST) v1.1 at baseline.

Exclusion criteria

Exclusion Criteria:

  1. Previous exposure to CEACAM5-targeted therapy.
  2. Prior treatment with a TOPO1-targeting ADC (CPT payload), such as Enhertu (trastuzumab deruxtecan) or Trodelvy (sacituzumab govitecan).
  3. History of another within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
  4. Active cerebral/meningeal disease related to the underlying malignancy. Participants with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior central nervous system disease has been treated and the participant is clinically stable (defined as not having received treatment for symptoms related to cerebral/meningeal disease for at least 2 weeks prior to enrollment and with no ongoing related AEs).

    > Criteria related to bevacizumab administration (participants in Parts D and E)

  5. History of allergic reactions or to bevacizumab or any of its .
  6. History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.
  7. Serious non-healing wound, non-healing ulcer, or non-healing bone fracture.
  8. Deep venous thromboembolic event within 4 weeks prior to enrollment
  9. Known coagulopathy that increases risk of bleeding, bleeding diatheses.
  10. History of any life-threatening VEGF-related adverse event
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
914 participants (estimated)

Study arms

  • Experimental
    PF-08046050

    PF-08046050 monotherapy

    Drug: PF-08046050

  • Experimental
    PF-08046050 +bevacizumab

    PF-08046050 combination with bevacizumab

    Drug: PF-08046050 · Drug: bevacizumab

  • Experimental
    PF-08046050 + bevacizumab + 5FU/LV

    PF-08046050 combination with bevacizumab + 5FU/LV

    Drug: PF-08046050 · Drug: bevacizumab · Drug: 5-Fluorouracil (5-FU) · Drug: Leucovorin (LV)

  • Experimental
    PF-08046050 + 5FU/LV + oxaliplatin + bevacizumab

    PF-08046050 combination with 5FU/LV + oxaliplatin + bevacizumab

    Drug: PF-08046050 · Drug: bevacizumab · Drug: 5-Fluorouracil (5-FU) · Drug: Oxaliplatin · Drug: Leucovorin (LV)

  • Experimental
    PF-08046050 + 5FU/LV + oxaliplatin

    PF-08046050 combination with 5FU/LV + oxaliplatin

    Drug: PF-08046050 · Drug: 5-Fluorouracil (5-FU) · Drug: Oxaliplatin · Drug: Leucovorin (LV)

  • Experimental
    PF-08046050 + 5FU/LV

    PF-08046050 combination with 5FU/LV

    Drug: PF-08046050 · Drug: 5-Fluorouracil (5-FU) · Drug: Leucovorin (LV)

Interventions

  • DrugPF-08046050

    Given into the vein (IV; intravenous)

    Also known as: SAR445953; SGN-CEACAM5C

  • Given into the vein (IV; intravenous)

  • Given into the vein (IV; intravenous)

  • Given into the vein (IV; intravenous)

  • Given into the vein (IV; intravenous)

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  2. Number of participants with laboratory abnormalities

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  3. Number of dose modifications due to AEs

    Time frame: Through end of treatment up to approximately 2 years

  4. Number of participants with dose-limiting toxicities (DLTs)

    Time frame: Up to 28 days

  5. Number of participants with DLTs by dose level

    Time frame: Up to 28 days

Secondary outcomes

  1. Pharmacokinetic (PK) parameter - Area under the concentration-time curve (AUC)

    PK endpoint

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  2. PK parameter - Maximum concentration (Cmax)

    PK endpoint

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  3. PK parameter - Time to maximum concentration (Tmax)

    PK endpoint

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  4. PK parameter - Trough concentration (Ctrough)

    PK endpoint

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  5. Number of participants with antidrug antibodies (ADAs)

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  6. Objective response rate (ORR)

    The objective response rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) which is subsequently confirmed as assessed according to Response Evaluation in Solid Tumors (RECIST) v1.1.

    Time frame: Through end of study and up to approximately 2 years

  7. Best overall response

    The best overall response for a participant will be determined by the order of confirmed CR, confirmed PR, stable disease (SD), progressive disease (PD), not evaluable (NE) or not applicable (NA) per RECIST v1.1.

    Time frame: Through end of study and up to approximately 2 years

  8. Duration of response (DOR)

    DOR is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per RECIST v1.1 or to death due to any cause

    Time frame: Through end of study and up to approximately 2 years

  9. Progression-free survival (PFS)

    PFS is defined as the time from start of SGN-CEACAM5C to first documentation of disease progression (based on radiographic assessments per RECIST v1.1) or death due to any cause, whichever comes first

    Time frame: Through end of study and up to approximately 2 years

  10. Overall survival (OS)

    OS is defined as the time from start of SGN-CEACAM5C to date of death due to any cause

    Time frame: Through end of study and up to approximately 2 years

07

Study locations

43 of 48 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Sep 2029, 69 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 69 months is above that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Nov 14, 2023
StartActual
Nov 20, 2023
Primary completionEst.
Sep 12, 2029
CompletionEst.
Sep 12, 2030
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06131840
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
Nov 20, 2023
Primary completion
Sep 12, 2029 (estimated)
Completion
Sep 12, 2030 (estimated)
Last update
Jul 22, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion